Denali Therapeutics Inc. (DNLI)
| Market Cap | 3.88B +80.5% |
| Revenue (ttm) | 3.60M |
| Net Income | -511.45M |
| EPS | -2.83 |
| Shares Out | 159.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 524,084 |
| Open | 24.17 |
| Previous Close | 24.35 |
| Day's Range | 24.01 - 24.49 |
| 52-Week Range | 12.58 - 27.30 |
| Beta | 1.00 |
| Analysts | Strong Buy |
| Price Target | 35.44 (+46.02%) |
| Earnings Date | Aug 6, 2026 |
About DNLI
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzym... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for DNLI stock is "Strong Buy." The 12-month stock price target is $35.44, which is an increase of 46.02% from the latest price.
News
Denali Therapeutics price target raised to $40 from $36 at Morgan Stanley
Morgan Stanley analyst Sean Laaman raised the firm’s price target on Denali Therapeutics (DNLI) to $40 from $36 and keeps an Overweight rating on the shares.
Denali Therapeutics price target raised to $34 from $25 at UBS
UBS raised the firm’s price target on Denali Therapeutics (DNLI) to $34 from $25 and keeps a Buy rating on the shares.
Denali Therapeutics price target raised to $34 from $31 at Baird
Baird raised the firm’s price target on Denali Therapeutics (DNLI) to $34 from $31 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results…
Denali Therapeutics Earnings Call Transcript: Q2 2026
AVLAYAH's first full commercial quarter generated $3.6M in revenue, with strong physician and patient engagement and over 50% payer coverage. Cash reserves exceed $1.1B, supporting a robust pipeline and guidance for Q3 revenue of $10–12M.
Denali Therapeutics Quarterly report: Q2 2026
Denali Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Denali Therapeutics Earnings release: Q2 2026
Denali Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Denali Therapeutics reports Q2 EPS (68c), consensus (47c)
Reports Q2 revenue $3.6M, consensus $2.19M. “We are excited by the positive response to our AVLAYAH launch from the Hunter syndrome community and the physicians caring for these patients. It…
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Strong first full quarter of AVLAYAH™ (tividenofusp alfa-eknm) launch generated $3.6 million in net product revenue Advanced TransportVehicle™ portfolio with two Alzheimer's disease programs now in cl...
Denali Therapeutics treatment of frontotemporal dementia granted orphan status
Denali Therapeutics (DNLI)’ progranulin replacement therapy was granted FDA orphan designation as a treatment of frontotemporal dementia, according to a post to the agency’s website.
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the second quar...
Denali Therapeutics price target raised to $36 from $35 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Denali Therapeutics (DNLI) to $36 from $35 and keeps an Overweight rating on the shares. Q2 earnings should reinforce a shift from…
Denali Therapeutics price target raised to $35 from $31 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Denali Therapeutics (DNLI) to $35 from $31 and keeps a Buy rating on the shares. The firm views the stock’s selloff on…
Denali Therapeutics falls -14.1%
Denali Therapeutics (DNLI) is down -14.1%, or -$3.73 to $22.75.
Denali Therapeutics falls -12.4%
Denali Therapeutics (DNLI) is down -12.4%, or -$3.28 to $23.20.
Denali Therapeutics price target raised to $26 from $20 at Wedbush
Wedbush analyst Laura Chico raised the firm’s price target on Denali Therapeutics (DNLI) to $26 from $20 and keeps an Outperform rating on the shares. The firm updated its model…
Denali Therapeutics resumed with an Overweight at JPMorgan
JPMorgan resumed coverage of Denali Therapeutics (DNLI) with an Overweight rating and $29 price target The firm says Denali is executing on the build-out of its commercial presence following the…
Denali Therapeutics to Give Opening Plenary Address at Alzheimer's Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier
SOUTH SAN FRANCISCO, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that co-founder and Chief Executive Officer Ryan Watts, Ph.D., will deliver the o...
Denali Therapeutics enters agreement to sell Rare Pediatric Disease PRV
Denali Therapeutics (DNLI) announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher, PRV, for gross proceeds of $195M. The U.S. Food and…
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
SOUTH SAN FRANCISCO, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Pri...
Denali Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
AVLAYAH’s launch for Hunter syndrome is progressing well, with strong field enthusiasm and payer acceptance. The pipeline includes upcoming data for Sanfilippo, Pompe, and Alzheimer’s, with key regulatory and commercial milestones expected by 2027. The Transport Vehicle platform is positioned as a differentiated, FDA-approved technology in a competitive landscape.
Denali Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
AVLAYAH’s approval marks a breakthrough in blood-brain barrier drug delivery, with rapid launch uptake and a robust pipeline targeting neurodegenerative and lysosomal diseases. Upcoming data from Sanfilippo, FTD, and Alzheimer’s programs, plus ongoing COMPASS and BEACON studies, are expected to drive further growth and label expansion.
Denali Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum, reviewed the agenda, and held votes on director elections, auditor ratification, and executive compensation. All proposals passed, with final results to be filed in a Form 8-K. A Q&A session was also provided.
Denali Therapeutics price target lowered to $35 from $40 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Denali Therapeutics (DNLI) to $35 from $40 and keeps an Overweight rating on the shares. The Phase 2b LUMA study failed to…
Denali Therapeutics price target lowered to $31 from $35 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Denali Therapeutics (DNLI) to $31 from $35 and keeps a Buy rating on the shares.
Denali Therapeutics trading resumes
18:35 EDT Denali Therapeutics (DNLI) trading resumes